Cardiff Oncology Reports FY2025 Results, Plans Registrational Program for Onvansertib in RAS-Mutated mCRC

Cardiff Oncology reported full-year 2025 results, with royalty revenues at $0.6 million and total operating expenses at $49.6 million. The company's net loss was $45.9 million, or $0.69 per share. Cash, cash equivalents, and short-term investments totaled $58.3 million, expected to fund operations into Q1 2027. Cardiff announced positive Phase 2 trial data for Onvansertib in RAS-mutated mCRC, with plans to advance the 30 mg dose into a registrational program. The company also reported preliminary efficacy in CMML.